FR3122084B1 - Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. - Google Patents

Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. Download PDF

Info

Publication number
FR3122084B1
FR3122084B1 FR2104166A FR2104166A FR3122084B1 FR 3122084 B1 FR3122084 B1 FR 3122084B1 FR 2104166 A FR2104166 A FR 2104166A FR 2104166 A FR2104166 A FR 2104166A FR 3122084 B1 FR3122084 B1 FR 3122084B1
Authority
FR
France
Prior art keywords
skin
bioactives
intestine
intestinal
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2104166A
Other languages
English (en)
Other versions
FR3122084A1 (fr
Inventor
Mizuho Nasu
Bejit Ideas
Yuki Murata
Jean-Yves Bruxer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirei Int Ltd
Original Assignee
Mirei Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirei Int Ltd filed Critical Mirei Int Ltd
Priority to FR2104166A priority Critical patent/FR3122084B1/fr
Publication of FR3122084A1 publication Critical patent/FR3122084A1/fr
Application granted granted Critical
Publication of FR3122084B1 publication Critical patent/FR3122084B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Composition cosmétique ou pharmaceutique comprenant une association de bioactifs sélectionnés à partir de graines de Glycine max, parmi le groupe : citrulline, taurine, proline, phosphatidylsérine, GABA, ornithine, histidine, leucine, lipoteichoic acid, biotine, cystéine, éctoïne, acide malique, pour leur utilisation dans le traitement ou la prévention de la dysbiose intestinale et/ou cutanée, l’équilibre de l’axe intestin-peau-cerveau et pour l’amélioration des troubles de l’humeur.
FR2104166A 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. Active FR3122084B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2104166A FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2104166 2021-04-21
FR2104166A FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.

Publications (2)

Publication Number Publication Date
FR3122084A1 FR3122084A1 (fr) 2022-10-28
FR3122084B1 true FR3122084B1 (fr) 2023-10-27

Family

ID=77021427

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2104166A Active FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.

Country Status (1)

Country Link
FR (1) FR3122084B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2136825T3 (pl) 2007-03-01 2014-04-30 Probi Ab Zastosowanie bakterii lactobacillus plantarum do zwiększania różnorodności bakteryjnej
CA2902248A1 (fr) 2013-03-15 2014-09-25 Microbiome Therapeutics, Llc Fibre de cosse de soja activee
WO2015159125A1 (fr) 2014-04-15 2015-10-22 Compagnie Gervais Danone Utilisation de lactobacillus rhamnosus pour favoriser le rétablissement de la diversité du microbiote intestinal d'un sujet après dysbiose provoquée par des antibiotiques
CN107648057A (zh) * 2017-10-21 2018-02-02 诺斯贝尔化妆品股份有限公司 一种长效保湿修复生物纤维面膜
CN110339206A (zh) * 2019-07-30 2019-10-18 岳茂兴 一种用于治疗顽固性痤疮的药物组合物及其应用

Also Published As

Publication number Publication date
FR3122084A1 (fr) 2022-10-28

Similar Documents

Publication Publication Date Title
Ruparel et al. Direct effect of intracanal medicaments on survival of stem cells of the apical papilla
Miklós et al. Reorganization of synaptic inputs to the hypothalamic paraventricular nucleus during chronic psychogenic stress in rats
Won et al. Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion
Wang et al. Novel metformin-containing resin promotes odontogenic differentiation and mineral synthesis of dental pulp stem cells
Huang et al. Icariin regulates the bidirectional differentiation of bone marrow mesenchymal stem cells through canonical Wnt signaling pathway
Ren et al. Sestrin2 modulates cardiac inflammatory response through maintaining redox homeostasis during ischemia and reperfusion
Song et al. Agmatine enhances neurogenesis by increasing ERK1/2 expression, and suppresses astrogenesis by decreasing BMP 2, 4 and SMAD 1, 5, 8 expression in subventricular zone neural stem cells
Liu et al. In vitro cell behaviors of bone mesenchymal stem cells derived from normal and postmenopausal osteoporotic rats
Niu et al. Nardosinone suppresses RANKL-induced osteoclastogenesis and attenuates lipopolysaccharide-induced alveolar bone resorption
FR3122084B1 (fr) Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.
Khan et al. Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism
Giannopoulos et al. L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered
Sun et al. Cytotoxic Effects of One-step Self-etching Dental Adhesives on Human Periodontal Ligament Fibroblasts In Vitro.
Latif et al. Change in cationic amino acid transport system and effect of lysine pretreatment on inflammatory state in amyotrophic lateral sclerosis cell model
FR3067349B1 (fr) Nouveaux agents mono et di-antennes complexants hydrosolubles et complexes de lanthanide correspondants
Morisbak et al. In vitro effects of dental monomer exposure-Dependence on the cell culture model
Olivares-Navarrete et al. Role of the N-terminal peptide of amelogenin on osteoblastic differentiation of human mesenchymal stem cells
Schlueter et al. L929 fibroblast bioassay on the in vitro toxicity of SnCl2, H3PO4, Clearfil SE primer and combinations thereof
Damaiyanti et al. Effectiveness of gold sea cucumber (Stichopus hermanii) extracts in accelerating the healing process of oral traumatic ulcer in rats
Yu et al. Krüppel-like factor 15 is a key suppressor of podocyte fibrosis under rotational force-driven pressure
FR3097743B1 (fr) Produit de combinaison pour aider au maintien des défenses naturelles de l’organisme
Gueux et al. Plasma and erythrocyte magnesium levels in a French population.
Su et al. The effective role of sodium copper chlorophyllin on the dysfunction of bone marrow mesenchymal stem cells in multiple myeloma via regulating TGF-β1
FR3099698B1 (fr) Produit de combinaison pour aider au maintien des défenses naturelles de l’organisme et à retrouver la forme
EP4218784A3 (fr) Modulateurs macrocycliques de mauvais repliement et d'agrégation de protéines associés à une maladie

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221028

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4